Pharmacotherapy and herbal treatment of benign prostatic hyperplasia

被引:3
作者
Sun, Jianming [1 ]
Zhang, Xiaoping [2 ]
机构
[1] Shanghai Seventh Peoples Hosp, Shanghai 200137, Peoples R China
[2] Tongji Univ, Peoples Hosp 10, Dept Nucl Med, Shanghai, Peoples R China
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2014年 / 19卷
关键词
Benign prostatic hyperplasia; lower urinary tract symptoms; pharmacotherapy; Western medicine; Chinese herbal medicine; Review; URINARY-TRACT SYMPTOMS; AMERICAN-UROLOGICAL-ASSOCIATION; TRADITIONAL CHINESE MEDICINE; QUALITY-OF-LIFE; COMBINATION THERAPY; OVERACTIVE BLADDER; CLINICAL PROGRESSION; ENLARGED PROSTATE; SAW PALMETTO; MEN;
D O I
10.2741/4246
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Benign prostatic hyperplasia (BPH) is the most common tumor in aging men, and is associated with lower urinary tract symptoms (LUTS). Treatment options include watchful waiting, life-style modification, pharmacologic treatment, and surgery. Alpha-adrenergic receptor blockers (alpha-blockers) decrease LUTS and increase urinary flow rates in men with symptomatic BPH. 5-Alpha-reductase inhibitors (5-ARIs) decrease the production of dihydrotestosterone within the prostate, which results in decreased prostate volume. For patients with moderate to severe symptoms and a large prostate, combination therapy with a-blockers and 5-ARIs can further improve clinical efficacy of treatment. Numerous plant-based products (phytomedicines) are increasingly used as an alternative or complement the conventional medication. For some patients, phosphodiesterase-5 inhibitors (PDE5-Is) or antimuscarinic agents may be added. Here, we discuss the current pharmacotherapy of BPH.
引用
收藏
页码:789 / 797
页数:9
相关论文
共 71 条
[1]   Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction [J].
Abrams, P ;
Kaplan, S ;
Gans, HJD ;
Millard, R .
JOURNAL OF UROLOGY, 2006, 175 (03) :999-1004
[2]   Tadalafil for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Pathophysiology and Mechanism(s) of Action [J].
Andersson, Karl-Erik ;
de Groat, William C. ;
McVary, Kevin T. ;
Lue, Tom F. ;
Maggi, Mario ;
Roehrborn, Claus G. ;
Wyndaele, Jean Jacques ;
Melby, Thomas ;
Viktrup, Lars .
NEUROUROLOGY AND URODYNAMICS, 2011, 30 (03) :292-301
[3]   Urinary bladder contraction and relaxation: Physiology and pathophysiology [J].
Andersson, KE ;
Arner, A .
PHYSIOLOGICAL REVIEWS, 2004, 84 (03) :935-986
[4]   Effect of Dutasteride on the Risk of Prostate Cancer. [J].
Andriole, Gerald L. ;
Bostwick, David G. ;
Brawley, Otis W. ;
Gomella, Leonard G. ;
Marberger, Michael ;
Montorsi, Francesco ;
Pettaway, Curtis A. ;
Tammela, Teuvo L. ;
Teloken, Claudio ;
Tindall, Donald J. ;
Somerville, Matthew C. ;
Wilson, Timothy H. ;
Fowler, Ivy L. ;
Rittmaster, Roger S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (13) :1192-1202
[5]   Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction:: A prospective, randomized, controlled study [J].
Athanasopoulos, A ;
Gyftopoulos, K ;
Giannitsas, K ;
Fisfis, J ;
Perimenis, P ;
Barbalias, G .
JOURNAL OF UROLOGY, 2003, 169 (06) :2253-2256
[6]  
Azimi Hanieh, 2012, Inflammation & Allergy Drug Targets, V11, P207
[7]  
Badmus T A, 2012, Niger Postgrad Med J, V19, P15
[8]   Phytotherapeutic agents in the treatment of lower urinary tract symptoms: A demographic analysis of awareness and use at the University of Chicago [J].
Bales, GT ;
Christiano, AP ;
Kirsh, EJ ;
Gerber, GS .
UROLOGY, 1999, 54 (01) :86-89
[9]   Effect of Increasing Doses of Saw Palmetto Extract on Lower Urinary Tract Symptoms A Randomized Trial [J].
Barry, Michael J. ;
Meleth, Sreelatha ;
Lee, Jeannette Y. ;
Kreder, Karl J. ;
Avins, Andrew L. ;
Nickel, J. Curtis ;
Roehrborn, Claus G. ;
Crawford, E. David ;
Foster, Harris E., Jr. ;
Kaplan, Steven A. ;
McCullough, Andrew ;
Andriole, Gerald L. ;
Naslund, Michael J. ;
Williams, O. Dale ;
Kusek, John W. ;
Meyers, Catherine M. ;
Betz, Joseph M. ;
Cantor, Alan ;
McVary, Kevin T. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (12) :1344-1351
[10]   BENIGN PROSTATIC HYPERPLASIA SPECIFIC HEALTH-STATUS MEASURES IN CLINICAL RESEARCH - HOW MUCH CHANGE IN THE AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX AND THE BENIGN PROSTATIC HYPERPLASIA IMPACT INDEX IS PERCEPTIBLE TO PATIENTS [J].
BARRY, MJ ;
WILLIFORD, WO ;
CHANG, YC ;
MACHI, M ;
JONES, KM ;
WALKERCORKERY, E ;
LEPOR, H .
JOURNAL OF UROLOGY, 1995, 154 (05) :1770-1774